Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug-Receptor Interactions01:29

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue.
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
The Two-State Receptor Model01:29

The Two-State Receptor Model

The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with one...
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Production of Pharmaceuticals01:30

Production of Pharmaceuticals

Industrial insulin production uses genetically engineered E. coli expressing a proinsulin gene controlled by a tryptophan promoter and containing a methionine linker for later cleavage. The cells also carry ampicillin resistance for selective growth. Seed cultures are stored at −80 °C and production begins by thawing a small amount to inoculate starter cultures, which are progressively scaled to a 50,000-L bioreactor. In the bioreactor, E. coli grow in nutrient-rich media under sterile, tightly...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hyaluronic Acid-Alginate Hydrazone Crosslinked Hydrogels Support the Generation and Maturation of V2a Interneurons.

bioRxiv : the preprint server for biology·2026
Same author

Discovery and Characterization of Interleukin-4-Specific Affibodies for Affinity-Controlled Protein Release and Macrophage Polarization.

bioRxiv : the preprint server for biology·2026
Same author

Regenerative bone-targeted nanoparticles modulate osteoclast function.

Nanoscale horizons·2026
Same author

Recapitulating the Native Tendon Environment in a Synthetic 3D Anisotropic Hydrogel as an Engineered Extracellular Matrix.

ACS applied bio materials·2026
Same author

Melt Electrowritten Scaffold-Reinforced Affibody-Conjugated Hydrogels for Controlled Bone Morphogenetic Protein-2 Delivery.

bioRxiv : the preprint server for biology·2025
Same author

Hyaluronic Acid-Coated Melt Electrowritten Scaffolds Promote Myoblast Attachment, Alignment, and Differentiation.

Cellular and molecular bioengineering·2025

Related Experiment Video

Updated: Jun 20, 2026

Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

17.3K

Recombinant and Synthetic Affibodies Function Comparably for Modulating Protein Release.

Jonathan Dorogin1, Morrhyssey A Benz1,2, Cameron J Moore1

  • 1Department of Bioengineering, University of Oregon, Knight Campus, Eugene, Oregon USA.

Cellular and Molecular Bioengineering
|October 7, 2024
PubMed
Summary

Solid-phase peptide synthesis offers a viable alternative to recombinant production for bone morphogenetic protein-2 (BMP-2) specific affibodies. Synthetic affibodies exhibit comparable structure and function, with reduced endotoxin levels and increased yield for controlled release applications.

Keywords:
AffibodyBMP-2HydrogelPeptideRecombinant protein expressionSolid-phase peptide synthesis

More Related Videos

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.7K
Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
06:37

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

541

Related Experiment Videos

Last Updated: Jun 20, 2026

Laboratory Scale Production and Purification of a Therapeutic Antibody
09:54

Laboratory Scale Production and Purification of a Therapeutic Antibody

Published on: January 24, 2017

17.3K
In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
07:25

In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis

Published on: May 4, 2017

17.7K
Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety
06:37

Using Reference Reagents to Confirm Robustness of Cytokine Release Assays for the Prediction of Monoclonal Antibody Safety

Published on: September 15, 2023

541

Area of Science:

  • Biotechnology
  • Protein Engineering
  • Materials Science

Background:

  • Affibodies are versatile affinity proteins with therapeutic potential in imaging and targeted therapies.
  • Bone morphogenetic protein-2 (BMP-2) plays a crucial role in bone regeneration.
  • Controlling BMP-2 release from hydrogels is key for effective therapeutic delivery.

Purpose of the Study:

  • To compare recombinant and synthetically produced BMP-2-specific affibodies.
  • To evaluate the impact of affibody affinity on BMP-2 release from hydrogels.
  • To assess the purity, structure, and activity of both production methods.

Main Methods:

  • Recombinant expression in E. coli and solid-phase peptide synthesis (SPPS) for affibody production.
  • Circular dichroism and biolayer interferometry for structural and binding analysis.
  • Endotoxin assays (LAL) and ELISA for purity and controlled release quantification.

Main Results:

  • Both synthetic and recombinant affibodies showed comparable α-helical structures and BMP-2 binding affinities.
  • Synthetic affibodies were free of detectable endotoxins, unlike recombinant versions.
  • High-affinity affibody hydrogels demonstrated reduced cumulative BMP-2 release.

Conclusions:

  • Solid-phase peptide synthesis is a viable method for producing high-purity affibodies.
  • Synthetic affibodies offer advantages in reduced endotoxin contamination and increased yield.
  • Affibody affinity can be used to tune BMP-2 release kinetics from hydrogels.